CX1739

CX1739
臨床資料
其他名稱	CX-1739
法律規範狀態
法律規範	美：Investigational New Drug;
識別資訊
	IUPAC命名法 N-methyl-N-(oxan-4-yl)-2,1,3-benzoxadiazole-5-carboxamide; ;
CAS號	1086377-48-1
PubChem CID	25104045;
ChemSpider	103868867;
UNII	UPB5G360MA;
化學資訊
化學式	C13H15N3O3
摩爾質量	261.28 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CN(C1CCOCC1)C(=O)C2=CC3=NON=C3C=C2;
	InChI InChI=1S/C13H15N3O3/c1-16(10-4-6-18-7-5-10)13(17)9-2-3-11-12(8-9)15-19-14-11/h2-3,8,10H,4-7H2,1H3; Key:IRYRMRDDVXULFG-UHFFFAOYSA-N;

CX1739是一種由Cortex藥業（現為RespireRx）開發的研究性新藥，目前正在評估其用於治療多種疾病，例如注意力不足過動症^[1]、自閉症^[2]、阿片引發的呼吸抑制^[3]^[4]及中樞神經性睡眠呼吸暫停（英語：Central sleep apnea）。^[5]

合成

CX1739可由可由苯並呋咱-5-甲酸和N-甲基四氫吡喃-4-胺反應製得。^[6]

參考文獻

^ Radin DP, Lippa A, Rana S, Fuller DD, Smith JL, Cerne R, Witkin JM. Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today. Pharmacology, Biochemistry, and Behavior. 2025, 248: 173967. PMC 11849398 . PMID 39894310. doi:10.1016/j.pbb.2025.173967. 已忽略未知參數|pmc-embargo-date= (幫助)
^ Silverman J, Oliver C, Karras M, Gastrell P, Crawley J. AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013, 64 (1): 268–282. PMC 3445667 . PMID 22801296. doi:10.1016/j.neuropharm.2012.07.013.
^ Radin DP, Zhong S, Cerne R, Shoaib M, Witkin JM, Lippa A. Low-Impact Ampakine CX1739 Exerts Pro-Cognitive Effects and Reverses Opiate-Induced Respiratory Depression in Rodents. Future Pharmacology. 2024, 4: 173–187. doi:10.3390/futurepharmacol4010012 .
^ Xiao D, Xie F, Xu X, Zhou X. The Impact and Mechanism of Ampakine CX1739 on Protection Against Respiratory Depression in Rats. Future Medicinal Chemistry. 2020, 12 (23): 2093–2104. PMID 33030058. doi:10.4155/fmc-2020-0256.
^ Ren J, Ding X, Greer JJ. Ampakines Enhance Weak Endogenous Respiratory Drive and Alleviate Apnea in Perinatal Rats. American Journal of Respiratory and Critical Care Medicine. 2015, 191 (6): 704–710. PMID 25594679. doi:10.1164/rccm.201410-1898OC.
^ Xiao, Dian; et al. The impact and mechanism of ampakine CX1739 on protection against respiratory depression in rats. Future Medicinal Chemistry (2020), 12(23), 2093-2104. doi:10.4155/fmc-2020-0256.

[Radin_2025-1] Radin DP, Lippa A, Rana S, Fuller DD, Smith JL, Cerne R, Witkin JM. Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today. Pharmacology, Biochemistry, and Behavior. 2025, 248: 173967. PMC 11849398 . PMID 39894310. doi:10.1016/j.pbb.2025.173967. 已忽略未知參數|pmc-embargo-date= (幫助)

[Silverman_2013-2] Silverman J, Oliver C, Karras M, Gastrell P, Crawley J. AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013, 64 (1): 268–282. PMC 3445667 . PMID 22801296. doi:10.1016/j.neuropharm.2012.07.013.

[Radin_2024-3] Radin DP, Zhong S, Cerne R, Shoaib M, Witkin JM, Lippa A. Low-Impact Ampakine CX1739 Exerts Pro-Cognitive Effects and Reverses Opiate-Induced Respiratory Depression in Rodents. Future Pharmacology. 2024, 4: 173–187. doi:10.3390/futurepharmacol4010012 .

[Xiao_2020-4] Xiao D, Xie F, Xu X, Zhou X. The Impact and Mechanism of Ampakine CX1739 on Protection Against Respiratory Depression in Rats. Future Medicinal Chemistry. 2020, 12 (23): 2093–2104. PMID 33030058. doi:10.4155/fmc-2020-0256.

[Ren_2015-5] Ren J, Ding X, Greer JJ. Ampakines Enhance Weak Endogenous Respiratory Drive and Alleviate Apnea in Perinatal Rats. American Journal of Respiratory and Critical Care Medicine. 2015, 191 (6): 704–710. PMID 25594679. doi:10.1164/rccm.201410-1898OC.

[6] Xiao, Dian; et al. The impact and mechanism of ampakine CX1739 on protection against respiratory depression in rats. Future Medicinal Chemistry (2020), 12(23), 2093-2104. doi:10.4155/fmc-2020-0256.

[1]

[2]

[3]

[4]

[5]

[6]